-
公开(公告)号：US11141377B2
公开(公告)日：2021-10-12
申请号：US16622908
申请日：2018-06-15
Applicant: Infectious Disease Research Institute
Inventor： Christopher B. Fox , Amit Praful Khandhar , Neal Van Hoeven , Jesse H. Erasmus , Susan S. Lin
Abstract: Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.
-
12.发明授权公开(公告)号：US11091521B2
公开(公告)日：2021-08-17
申请号：US15815512
申请日：2017-11-16
Applicant: Infectious Disease Research Institute
Inventor： Steven G. Reed , Rhea N. Coler , Gregory C. Ireton , Sylvie Bertholet
IPC: C07K14/35 , A61K39/04 , C07K14/285 , A61K39/00 , G01N33/569 , G01N33/68
Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.
-
公开(公告)号：US20190298819A1
公开(公告)日：2019-10-03
申请号：US16315986
申请日：2017-07-07
Applicant: Hawaii Biotech Inc. , Infectious Disease Research Institute
Inventor： David E. Clements , Neal Van Hoeven
Abstract: A West Nile virus (WNV) vaccine for human use is described that contains a recombinantly produced form of truncated WNV envelope glycoprotein and a combination of a Toll-like receptor 4 (TLR-4) and saponin adjuvants. A pharmaceutically acceptable vehicle may also be included in the vaccine.
-
公开(公告)号：US09987355B2
公开(公告)日：2018-06-05
申请号：US13930953
申请日：2013-06-28
Applicant: Infectious Disease Research Institute
Inventor： Steven G. Reed , Darrick Carter
IPC: A61K39/39 , A61K9/107 , A61K39/00 , A61K39/35 , A61K45/06 , A61K39/008 , A61K39/04 , A61K39/145
CPC classification number: A61K39/39 , A61K9/107 , A61K39/0011 , A61K39/008 , A61K39/04 , A61K39/145 , A61K39/35 , A61K45/06 , A61K2039/55511 , A61K2039/55572 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/396 , Y02A50/41 , Y02A50/491
Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
-
15.发明授权Fusion proteins and their use in the diagnosis and treatment of leishmaniasis 有权融合蛋白及其在利什曼病诊断和治疗中的应用公开(公告)号：US09279005B2
公开(公告)日：2016-03-08
申请号：US14286647
申请日：2014-05-23
Applicant: Infectious Disease Research Institute
Inventor： Ajay Bhatia , Steven G. Reed
IPC: G01N33/569 , C12P21/04 , A61K39/008 , C07K14/44 , G01N33/68 , C07K16/20 , A61K38/00 , A61K39/00
CPC classification number: C07K14/44 , A61K38/00 , A61K39/00 , C07K16/20 , G01N33/56905 , G01N33/6893 , Y10S435/81 , Y10S435/975
Abstract: The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.
Abstract translation: 本发明一般涉及由包含源自利什曼原虫抗原K26，K39和K9的元件的合成基因构建体制成的融合蛋白。 融合蛋白特别可用于诊断利什曼病，特别是动物如人和狗中的内脏利什曼病。
-
Patent Agency Ranking
公开(公告)号：US20220160632A1
公开(公告)日：2022-05-26
申请号：US17560594
申请日：2021-12-23
Inventor： Christopher B. Fox , Susan S. Lin , Darrick Carter , Neal Van Hoeven , Mayuresh M. Abhyankar , William A. Petri
IPC: A61K9/127 , A61K31/739 , A61K39/39
Abstract: Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.
-
公开(公告)号：US10765736B2
公开(公告)日：2020-09-08
申请号：US15823852
申请日：2017-11-28
Applicant: Infectious Disease Research Institute
Inventor： Steven G. Reed , Darrick Carter
IPC: A61K39/395 , A61K39/39 , A61K9/107 , A61K39/00 , A61K39/35 , A61K45/06 , A61K39/008 , A61K39/04 , A61K39/145
Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
-
18.发明申请公开(公告)号：US20200148729A1
公开(公告)日：2020-05-14
申请号：US16098911
申请日：2017-05-19
Applicant: Infectious Disease Research Institute
Inventor： Rhea N. Coler
Abstract: Provided herein are fusion polypeptides comprising at least two Mycobacterial antigens, wherein one Mycobacterial antigen is a strong central memory T cell activator, and wherein one Mycobacterial antigen is a strong effector memory T cell activator. Also provided herein are methods of making and using such fusion polypeptides for the prevention or treatment of a secondary Mycobacterium tuberculosis infection as well as for the prevention or treatment of a nontuberculous Mycobacterium infection in a mammal.
-
公开(公告)号：US20190328868A1
公开(公告)日：2019-10-31
申请号：US16473393
申请日：2017-12-20
Inventor： Hyo Jung NAM , Eun Mi KIM , Duck Hyang SHIN , Steven G. REED , Kang Il YOO , Sung Jun HONG
IPC: A61K39/25 , A61K39/39 , A61P31/22 , G01N33/569
Abstract: The present invention relates to a herpes zoster vaccine composition, which comprises glycoprotein E of Varicella zoster virus, a glucopyranosyl lipid adjuvant, and a metabolic oil, and selectively increases a cell-mediated immune reaction without having disadvantages of attenuated live vaccines, thereby exhibit high safety and a high preventive effect against herpes zoster.
-
公开(公告)号：US20180236063A1
公开(公告)日：2018-08-23
申请号：US15875517
申请日：2018-01-19
Applicant: Infectious Disease Research Institute
Inventor： Steven G. Reed , Darrick Carter
IPC: A61K39/39 , A61K39/008 , A61K39/145 , A61K39/00 , A61K39/04 , A61K39/35 , A61K9/107 , A61K45/06
Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
-
-
-
-
-
-
-
-
-
Search Results
59
records
(took 0.023 seconds)
